|
Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. |
|
|
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines. |
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech; Novartis; Novartis; Roche |
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Research Funding - Roche (Inst) |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis |
|
|
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Proacta |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Novartis; Proacta |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis |
Patents, Royalties, Other Intellectual Property - University Hospital, Essen |
|
|
Travel, Accommodations, Expenses - Amgen; Novartis; Pfizer; Proacta |
|
|
No Relationships to Disclose |
|
|
Employment - Zimmer BioMet (I) |
Consulting or Advisory Role - Janssen Oncology; Karyopharm Therapeutics; Threshold Pharmaceuticals |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); eleison pharmaceuticals (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Janssen (Inst); Lilly (Inst); medpacto (Inst); pfizer (Inst); Plexxikon (Inst); Roche (Inst); Threshold Pharmaceuticals (Inst) |
|
|
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi |
Research Funding - Janssen-Cilag (Inst); Merck Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Lilly; Merck Serono; MSD; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Merck |
|
|
Consulting or Advisory Role - Amgen; Celgene; Novartis; Takeda |
Research Funding - AstraZeneca |
Other Relationship - Amgen; Lilly; Proacta |
|
|
|
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Atara Biotherapeutics; Chugai Pharma; CytomX Therapeutics |
Research Funding - AstraZeneca; Puma Biotechnology |
|
|
Leadership - Infinity Pharmaceuticals; Varian Medical Systems |
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems |
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL |